Evidence map›Paper›PMID 41583459›Full record

ArticleFrontiers in immunology2025

The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B.

Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaxin Han *The Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Lianxin Xu *The Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Yuqin LiThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Ziling WangThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Minghui ZengThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Jieru GaoThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Yuqiang MiDepartment of Infectious Diseases, Tianjin Fourth Central Hospital, The Affiliated Hospital of Tianjin Medical University, Tianjin, China.
Wentao KuaiThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Huiling XiangDepartment of Gastroenterology and Hepatology, Tianjin University Central Hospital (The Third Central Hospital of Tianjin), Tianjin, China.
Liang XuThe Second People's Hospital Affiliated to Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the efficacy and prognosis of pegylated interferon (Peg-IFN)-based therapy for chronic hepatitis B (CHB) remains controversial and requires further investigation. Methods: A total of 620 CHB patients receiving Peg-IFN-based therapy were enrolled and categorized into MASLD-CHB (n = 247) and CHB (n = 373) groups. Propensity score matching (PSM) was employed to balance baseline differences. Kaplan-Meier survival analysis and LASSO-Cox regression were applied to identify independent predictors of complete virological response (CVR) and hepatitis B surface antigen (HBsAg) seroclearance. Results: After PSM, 247 patients were included in each group. Compared with the MASLD-CHB group, the CHB group exhibited significantly higher cumulative CVR rates at month 3 (36.84% Conclusion: In CHB patients receiving Peg-IFN-based therapy, concurrent MASLD may impede the reduction of HBV DNA levels, delay the time of first CVR, and potentially accelerate liver fibrosis progression.

Indexed as

Antiviral AgentsFatty LiverHepatitis B, ChronicInterferon-alphaPolyethylene GlycolsAdultFemaleHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedRecombinant ProteinsTreatment OutcomeAntiviral AgentsHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteinschronic hepatitis Befficacymetabolic dysfunction-associated steatotic liver diseaseoutcome eventspegylated interferon

Identifiers

PMID41583459
PMCPMC12827663

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.